Theranexus SA (ALTHX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.305x

Based on the latest financial reports, Theranexus SA (ALTHX) has a cash flow conversion efficiency ratio of -0.305x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-883.76K ≈ $-1.03 Million USD) by net assets (€2.90 Million ≈ $3.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Theranexus SA balance sheet quality to measure how much of total assets are equity-financed.

Theranexus SA - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Theranexus SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ALTHX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Theranexus SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Theranexus SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Derluks Yatirim Holding AS IS:DERHL	-0.038x
Lay Hong Bhd KLSE:9385	0.049x
Romerike Sparebank OL:ROMER	-0.198x
Information and Communication Networks Public Company Limited BK:ICN	0.114x
FTC Solar Inc NASDAQ:FTCI	2.077x
Metagenomi, Inc. Common Stock NASDAQ:MGX	-0.154x
TJGC Group Limited NASDAQ:TJGC	-1.130x
Impact BioMedical, Inc. NYSE MKT:IBO	0.225x

Annual Cash Flow Conversion Efficiency for Theranexus SA (2015–2025)

The table below shows the annual cash flow conversion efficiency of Theranexus SA from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see ALTHX company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€2.90 Million ≈ $3.39 Million	€-883.76K ≈ $-1.03 Million	-0.305x	-114.98%
2024-12-31	€-1.66 Million ≈ $-1.94 Million	€-3.37 Million ≈ $-3.94 Million	2.033x	+171.04%
2023-12-31	€2.22 Million ≈ $2.60 Million	€-6.36 Million ≈ $-7.43 Million	-2.862x	-205.08%
2022-12-31	€5.73 Million ≈ $6.70 Million	€-5.37 Million ≈ $-6.28 Million	-0.938x	-52.84%
2021-12-31	€10.18 Million ≈ $11.90 Million	€-6.25 Million ≈ $-7.31 Million	-0.614x	-11.20%
2020-12-31	€10.28 Million ≈ $12.02 Million	€-5.68 Million ≈ $-6.64 Million	-0.552x	-8.61%
2019-12-31	€9.98 Million ≈ $11.66 Million	€-5.07 Million ≈ $-5.93 Million	-0.508x	-21.77%
2018-12-31	€13.41 Million ≈ $15.68 Million	€-5.60 Million ≈ $-6.54 Million	-0.417x	-312.77%
2017-12-31	€18.71 Million ≈ $21.87 Million	€-1.89 Million ≈ $-2.21 Million	-0.101x	+99.38%
2016-12-31	€89.85K ≈ $105.05K	€-1.47 Million ≈ $-1.72 Million	-16.406x	-3069.12%
2015-12-31	€1.68 Million ≈ $1.96 Million	€-867.96K ≈ $-1.01 Million	-0.518x	--

About Theranexus SA

PA:ALTHX France Biotechnology

Market Cap

$72.09 Million

€61.67 Million EUR

Market Cap Rank

#22193 Global

#348 in France

Share Price

€4.27

Change (1 day)

-0.70%

52-Week Range

€1.57 - €4.37

All Time High

€22.70